The goal of the study is to characterize the epidemiologic data of the neonatal and infant cholestasis.
Study Type
OBSERVATIONAL
Enrollment
57
proteomic urine analysis
UH Bordeaux
Bordeaux, France
UH Limoges
Limoges, France
UH Montpellier
Montpellier, France
UH Toulouse
Toulouse, France
Gathering mother epidemiologic characteristics as assessed by pregancy informations collection
Date of child birth, course of pregnancy, occurrence of twin pregnancy, serology abnormalities, family background of liver desease, course of previous pregnancies
Time frame: Day 1 (inclusion)
Gathering new born epidemiologic characteristics as assessed by birth informations collection
Birth anamnesis, inclusion age, hepatic desease history, hemostasis workup, validated etiologic diagnosis and criteria for the diagnosis, specific and non-specific therapeutic care
Time frame: Day 1 (inclusion)
Epidemiologic characteristics follow up as assessed by medical monitoring
Desease evolution in the first year of life, clinical evaluation, biological evaluation, final diagnosis, complications of the sickness, existence of transplatation, death
Time frame: When children are between 12 and 18 months old
Homogenization of diagnosis and treatment of new born with the constitution and follow up of a prospective cohorte
Homogenize the care pathway of neonatal and infant cholestasis
Time frame: Up to 3 years
Extend the study to the national french territory using the hepatology association network
Use this study to start a national study
Time frame: Up to 3 years
Identification of proteomic profiles using the biologic collection gathered in the cohorte population
Identify one or more specific proteomic profile of neonatal cholestasis
Time frame: Up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.